Mechanisms of extracellular vesicle-mediated immune evasion in melanoma

Dieterich, Lothar C.

doi:10.3389/fimmu.2022.1002551

Cited by 11 publications

(7 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD27-expressing MPs supplied by the transfusion of platelet concentrates could, therefore, be involved in the failure of anti-CD27 immunotherapy. The mechanism of action of MPs has not yet been determined ( 28 – 34 ), but we suggest that MPs present in transfusion products may compete with cellular targets. We tested this hypothesis by performing assays of in vitro competition between MPs and cells ( Figure 6 ), with the same ratios of CD27-expressing MPs to cells as above.…”

Section: Resultsmentioning

confidence: 86%

“…It has been suggested that MPs are involved in resistance to anti-PD1 immunotherapies ( 28 – 34 ). CD27-expressing MPs supplied by the transfusion of platelet concentrates could, therefore, be involved in the failure of anti-CD27 immunotherapy.…”

Section: Resultsmentioning

confidence: 99%

“…Immune checkpoint targeting with monoclonal antibodies is a widely used immunotherapy approach for limiting tumor growth. The presence of microvesicles/MPs expressing PD1/PD-L1 is often associated with treatment responsiveness ( 28 – 34 ). However, the possibility of these MPs being transferred into the body in a context of polytransfusion is rarely considered.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

CD27+ microparticle interactions and immunoregulation of CD4+ T lymphocytes

et al. 2023

View full text Add to dashboard Cite

IntroductionAplasia and hematological malignancies are treated with platelet transfusions, which can have major immunomodulatory effects. Platelet concentrates (PCs) contain many immunomodulatory elements, including the platelets themselves, residual leukocytes, extracellular vesicles, such as microparticles (MPs), cytokines and other soluble elements. Two of these components, MPs and a soluble form of CD27 (sCD27), have been shown to play a particularly important role in immune system modulation. The loss of CD27 expression is an irreversible marker of terminal effector CD3+ T-lymphocyte (TL) differentiation, and the CD27+ MPs present in PCs may maintain CD27 expression on the surface of TLs, and, thus, the activation of these cells.MethodsIn this study, we phenotyped the CD27-expressing MPs present in PCs by microscale flow cytometry and investigated the interaction of these particles with CD4+ TLs. We cocultured MPs and PBMCs and determined the origin of the CD27 expressed on the surface of CD4+ TLs with the aid of two fluorochromes (BV510 for CD27 originating from MPs and BV786 for cellular CD27).ResultsWe showed that the binding of CD27- expressing MPs involved the CD70 molecule, which was also present on these MPs. Finally, the maintenance of CD27 expression on the surface of TLs by sorted CD27+ MPs led to activation levels lower than those observed with other types of MPs.DiscussionThese results for CD27-expressing MPs and their CD70-mediated targeting open up new possibilities for immunotherapy based on the use of MPs to maintain a phenotype or to target immune cells, for example. Moreover, decreasing the levels of CD27-expressing MPs in transfused platelets might also increase the chances of success for anti-CD27 monoclonal immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 86%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

CD27+ microparticle interactions and immunoregulation of CD4+ T lymphocytes

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[63] The exploration of EVs' pathological role, their use as biomarkers in clinical diagnosis, and their involvement in disease treatment, initially began in the field of cancer, yielding exciting results. [62][63][64] For example, in melanoma, EVs secreted by cancer cells inhibit the maturation of dendritic cells and the production of cytokines, [65] while EVs derived from glioma cells can decrease the local Tregs content, thus mediating immunosuppression. The combination and content of non-coding RNA (ncRNA) in EVs derived from tumor cells are often specific, giving them potential as disease diagnosis biomarkers, such as miR-21, miR-221, miR301a in glioma, [66] and miR-25, miR-222, miR-16, miR324-3p in breast cancer.…”

Section: Evsmentioning

confidence: 99%

Engineered Extracellular Vesicles in Wound Healing: Design, Paradigms, and Clinical Application

Liao,

Zhang,

Ouyang

et al. 2023

Small

View full text Add to dashboard Cite

The severe quality of life and economic burden imposed by non‐healing skin wounds, infection risks, and treatment costs are affecting millions of patients worldwide. To mitigate these challenges, scientists are relentlessly seeking effective treatment measures. In recent years, extracellular vesicles (EVs) have emerged as a promising cell‐free therapy strategy, attracting extensive attention from researchers. EVs mediate intercellular communication, possessing excellent biocompatibility and stability. These features make EVs a potential tool for treating a plethora of diseases, including those related to wound repair. However, there is a growing focus on the engineering of EVs to overcome inherent limitations such as low production, relatively fixed content, and targeting capabilities of natural EVs. This engineering could improve both the effectiveness and specificity of EVs in wound repair treatments. In light of this, the present review will introduce the latest progress in the design methods and experimental paradigms of engineered EVs applied in wound repair. Furthermore, it will comprehensively analyze the current clinical research status and prospects of engineered EVs within this field.

show abstract

“…Wieckowski et al demonstrated that tumor-derived sEVs carry Fas-L protein, which contributes to TME immune suppression by promoting Treg proliferation and CD8 + T cell apoptosis [ 119 , 120 ]. HSP72 and HSP105 in sEVs in the sera of melanoma, lung cancer and BC patients activate dendritic cells and trigger IL-6 production, which promote tumor invasion by increasing MMP9 expression [ 121 ].…”

Section: Tumor-derived Sevs Play Vital Roles In the Bc Microenvironmentmentioning

confidence: 99%

Tumor-Derived Small Extracellular Vesicles Involved in Breast Cancer Progression and Drug Resistance

Feng

Guo

Tanaka

et al. 2022

IJMS

View full text Add to dashboard Cite

Breast cancer is one of the most serious and terrifying threats to the health of women. Recent studies have demonstrated that interaction among cancer cells themselves and those with other cells, including immune cells, in a tumor microenvironment potentially and intrinsically regulate and determine cancer progression and metastasis. Small extracellular vesicles (sEVs), a type of lipid-bilayer particles derived from cells, with a size of less than 200 nm, are recognized as one form of important mediators in cell-to-cell communication. sEVs can transport a variety of bioactive substances, including proteins, RNAs, and lipids. Accumulating evidence has revealed that sEVs play a crucial role in cancer development and progression, with a significant impact on proliferation, invasion, and metastasis. In addition, sEVs systematically coordinate physiological and pathological processes, such as coagulation, vascular leakage, and stromal cell reprogramming, to bring about premetastatic niche formation and to determine metastatic organ tropism. There are a variety of oncogenic factors in tumor-derived sEVs that mediate cellular communication between local stromal cells and distal microenvironment, both of which are important in cancer progression and metastasis. Tumor-derived sEVs contain substances that are similar to parental tumor cells, and as such, sEVs could be biomarkers in cancer progression and potential therapeutic targets, particularly for predicting and preventing future metastatic development. Here, we review the mechanisms underlying the regulation by tumor-derived sEVs on cancer development and progression, including proliferation, metastasis, drug resistance, and immunosuppression, which coordinately shape the pro-metastatic microenvironment. In addition, we describe the application of sEVs to the development of cancer biomarkers and potential therapeutic modalities and discuss how they can be engineered and translated into clinical practice.

show abstract

Mechanisms of extracellular vesicle-mediated immune evasion in melanoma

Cited by 11 publications

References 56 publications

CD27+ microparticle interactions and immunoregulation of CD4+ T lymphocytes

CD27+ microparticle interactions and immunoregulation of CD4+ T lymphocytes

Engineered Extracellular Vesicles in Wound Healing: Design, Paradigms, and Clinical Application

Tumor-Derived Small Extracellular Vesicles Involved in Breast Cancer Progression and Drug Resistance

Contact Info

Product

Resources

About